Imagine Endotoxin-Free Biosimilars
We call them "Biobetters"
Thanks to the evolving regulations and X’PROCHEM’s advanced technology, we can now think about biosimilar medications free of endotoxins and without other rDNA production contaminants impurities i.e. “clean” biosimilars or “Biobetters”
With cost-containment pressure throughout the world, the biosimilar market is poised to grow. Whereas biosimilar is a clearly defined regulatory term, there is no universally accepted definition for “Biobetters”.
Regulators approve biosimilars on the basis of their high similarity to an already approved referenced biological. A biosimilar shall have no clinically meaningful differences in terms of safety and effectiveness from its reference product.
In contrast, we propose that a Biobetter produced by X’PROCHEM’s advanced mid-size protein technology, would have a structure that is identical to the referenced biological, not just similar. And thanks to our precise chemical synthesis technology, our Biobetter would be free of endotoxins and other rDNA contaminants, which are inevitable when using recombinant fermentation-based production.
These may generate strong differentiation against traditional biosimilars and provide great competitive advantages. Moreover, protection of the Biobetter through a “Process Patent” could certainly be attempted.
The company is approved by the French Ministry of Higher Education, Research and Innovation as an organization carrying out research and development work opening up tax credits for research (CIR). For our customers, this approval may give entitlement to a tax credit for all research and development work entrusted to X’PROCHEM.